Healthcare
Live Price
Offline$1.29
-5.15% today
Window Change
+0.00%
Window
Jun 23, 2025 → Jul 16, 2025
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 17 bars · Jun 23, 2025 → Jul 16, 2025
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Akoya Biosciences, Inc. (AKYA) is a Healthcare stock with a market cap of $64.44M. The stock last traded around $1.29 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jul 16, 2025). Baseline metrics include revenue growth of -15.5%, EPS growth of +21.7%, a dividend yield of 0.0%. What stands out right now is revenue -15.5%, EPS +21.7%, free cash flow +14.7% with operating margin -50.3% and ROIC -22.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines AKYA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
AKYA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
AKYA Max Drawdown
-6.77%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for AKYA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$42.4M
-22.7% YoY
FY Net Income
-$16.7M
+61.1% YoY
Free Cash Flow
-$10.1M
+75.4% YoY
Revenue Growth
-15.5%
EPS Growth
+21.7%
Gross Margin
63.9%
Net Margin
-62.8%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 82M | 97M | 75M | 55M | 42M |
| Gross Profit | 48M | 56M | 43M | 34M | 26M |
| Operating Income | -47M | -58M | -66M | -37M | -11M |
| EBITDA | -37M | -46M | -59M | -35M | -10M |
| Net Income | -55M | -63M | -71M | -43M | -17M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12M | 83M | 74M | 113M | 17M |
| Total Assets | 125M | 180M | 176M | 191M | 78M |
| Total Liabilities | 117M | 127M | 117M | 70M | 59M |
| Shareholder Equity | 8M | 54M | 59M | 121M | 18M |
| Total Debt | 84M | 86M | 76M | 33M | 35M |
| Net Debt | 72M | 3M | 2M | -81M | 18M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7M
+81.0% YoY
Capital Expenditures
3M
+35.3% YoY
Free Cash Flow
10M
+75.4% YoY
Key ratios
Gross Margin
63.9%
Operating Margin
-50.3%
Net Margin
-62.8%
ROE
-2796.1%
Debt / Equity
-14.22x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.